Didanosine, a new antiretroviral drug. A review
- PMID: 1437513
- DOI: 10.1007/BF01977617
Didanosine, a new antiretroviral drug. A review
Abstract
In this article the literature about didanosine, an antiretroviral drug, is reviewed. The mechanism of action, biochemical pharmacology, pharmacokinetics, and clinical results of phase-I trials are discussed. Serious adverse effects such as pancreatitis and peripheral neuropathy have occurred in these trials. An antiretroviral effect was observed in terms of an increase in CD4+ lymphocytes and a decrease in p24 antigen levels in HIV-infected individuals. Didanosine seems to be a promising drug against HIV infection, but knowledge about its clinical efficacy is scanty.
Similar articles
-
Didanosine: an updated review of its use in HIV infection.Drugs. 1999 Dec;58(6):1099-135. doi: 10.2165/00003495-199958060-00009. Drugs. 1999. PMID: 10651392 Review.
-
Didanosine. An update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease.Drugs. 1996 Dec;52(6):928-62. doi: 10.2165/00003495-199652060-00014. Drugs. 1996. PMID: 8957161 Review.
-
Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects.J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Mar 1;17(3):227-34. doi: 10.1097/00042560-199803010-00007. J Acquir Immune Defic Syndr Hum Retrovirol. 1998. PMID: 9495222 Clinical Trial.
-
Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections.Antimicrob Agents Chemother. 1996 Mar;40(3):767-71. doi: 10.1128/AAC.40.3.767. Antimicrob Agents Chemother. 1996. PMID: 8851608 Free PMC article. Clinical Trial.
-
Concise overview of the clinical pharmacokinetics of dideoxynucleoside antiretroviral agents.Pharm World Sci. 1995 Mar 24;17(2):25-30. doi: 10.1007/BF01875051. Pharm World Sci. 1995. PMID: 7795555 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials